346 related articles for article (PubMed ID: 34098219)
21. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.
Landras A; Reger de Moura C; Villoutreix BO; Battistella M; Sadoux A; Dumaz N; Menashi S; Fernández-Recio J; Lebbé C; Mourah S
Oncogene; 2022 Apr; 41(15):2254-2264. PubMed ID: 35217792
[TBL] [Abstract][Full Text] [Related]
22. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
23. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
[TBL] [Abstract][Full Text] [Related]
24. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
25. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
26. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
27. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
28. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
Front Immunol; 2022; 13():894110. PubMed ID: 35967450
[TBL] [Abstract][Full Text] [Related]
29. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
30.
Muñoz-Couselo E; Adelantado EZ; Ortiz C; García JS; Perez-Garcia J
Onco Targets Ther; 2017; 10():3941-3947. PubMed ID: 28860801
[TBL] [Abstract][Full Text] [Related]
31. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia.
Rinonce HT; Sastri DJ; Trisnawati F; Kameswari B; Ferronika P; Irianiwati
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1454. PubMed ID: 34110110
[TBL] [Abstract][Full Text] [Related]
32. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
[TBL] [Abstract][Full Text] [Related]
33. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.
Johnson DB; Lovly CM; Flavin M; Panageas KS; Ayers GD; Zhao Z; Iams WT; Colgan M; DeNoble S; Terry CR; Berry EG; Iafrate AJ; Sullivan RJ; Carvajal RD; Sosman JA
Cancer Immunol Res; 2015 Mar; 3(3):288-295. PubMed ID: 25736262
[TBL] [Abstract][Full Text] [Related]
34. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
Front Immunol; 2021; 12():691032. PubMed ID: 34290710
[TBL] [Abstract][Full Text] [Related]
35. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
[TBL] [Abstract][Full Text] [Related]
36. NRAS mutations in primary and metastatic melanomas of Japanese patients.
Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
[TBL] [Abstract][Full Text] [Related]
37. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.
Matter AV; Micaletto S; Urner-Bloch U; Dummer R; Goldinger SM
Oncologist; 2020 Nov; 25(11):e1593-e1597. PubMed ID: 32886824
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
